Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed?

Anthos Therapeutics’ anticoagulant poses a lower risk of bleeding events than Bayer and J&J’s Xarelto when used to prevent blood clots in atrial fibrillation patients, full results from a mid-stage trial suggest. Anthos is already ...